1. A method of treating pain in an individual, comprising the step of administering to the individual: a binding protein that binds to IL-1α and a binding protein that binds to IL-1β, where the binding proteins are administered to the individual in a mixture, simultaneously or sequentially； or a binding protein that binds to both IL-1α and IL-1β. 2. A method for treating pain according to claim 1, wherein the individual suffers from a pain condition selected from the group consisting of allodynia, hyperalgesia, and a combination of allodynia and hyperalgesia. 3. The method of claim 1, wherein said binding protein binding to IL-1α is an anti-IL-1α antibody. The method of claim 1, wherein said binding protein binding to IL-1β is an anti-IL-1β antibody. The method of claim 1, wherein said binding protein binding to IL-1α is an anti-IL-1α antibody and said binding protein binding to IL-1β is an anti-IL-1β antibody. The method of claim 1, wherein said binding protein that binds to both IL-1α and IL-1β is a bispecific antibody or an immunoglobulin binding protein with a double variable domain (DVD-Ig). The method of claim 1, wherein said binding protein binding to IL-1α and said binding protein binding to IL-1β are formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. The method of claim 1, wherein said binding protein that binds to both IL-1α and IL-1β is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. The method of claim 1, wherein said binding protein binding to IL-1α and said binding protein binding to IL-1β are crystallized. The method of claim 1, wherein said binding protein is1. Способ лечения боли у индивидуума, включающий стадию введения индивидууму:связывающего белка, связывающегося с ИЛ-1α, и связывающего белка, связывающегося с ИЛ-1β, где связывающие белки вводят индивидууму в смеси, одновременно или последовательно； илисвязывающего белка, связывающегося и с ИЛ-1α, и с ИЛ-1β.2.
